自己血清点眼が奏効した抗癌薬ティーエスワン®による角膜障害の2例

Instillation of autologous serum was effective in two cases of corneal disorders secondary to anticancer drug TS-1®

要約　背景：ティーエスワン^®（TS-1）はテガフール，ギメラシル，オテラシルカリウムを含む内服用の抗癌薬であり，流涙，結膜炎，角膜炎，角膜びらんなどが副作用として知られている。目的：TS-1^®の内服後に生じた角膜障害に自己血清の点眼が奏効した2症例の報告。症例：それぞれ81歳と82歳の男性で，胃癌の手術後にTS-1^®を約1年間内服していた。渦巻き状の角膜上皮下の混濁があり，休薬後に点眼で加療したが，それぞれ1眼で改善しなかった。20％自己血清点眼を1日6回行い，それぞれ3か月と2か月後に角膜障害が軽減し，視力がやや改善した。結論：TS-1^®の休薬後も継続する角膜上皮下混濁が，自己血清の点眼後に軽減した。

Abstract.　Purpose：To report two cases who developed corneal disorders after treatment with peroral anticancer drug,TS-1^®,following surgery for gastric cancer and who showed improved corneal disorders after topical treatment with autologous serum. Cases and Findings：Both were males aged 81 and 82 respectively. Both had received surgery for gastric cancer and had been treated with peroral TS-1^®for about one year each. Convoluted subepithelial opacity was present in the cornea in both cases. The opacity persisted in both cases after discontinuation of TS-1^®and treatment with conventional topical medications. Instillation of 20％ autologous serum 6 times daily resulted in improved corneal findings with partial improvement of visual acuity. Conclusion：Instillation of autologous serum was followed by improved corneal disorders that developed after prolonged systemic treatment with TS-1^®.